DnB Asset Management
ABCL icon

DnB Asset Management’s AbCellera Biologics ABCL Stock Holding History

DnB Asset Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.32M Buy
+677,479
New +$3.31M 0.01% 473
2025
Q4 		– Sell
-656,208
Closed -$3.3M – 732
2025
Q3 		$3.3M Buy
+656,208
New +$2.89M 0.01% 511
2025
Q1 		– Sell
-305,579
Closed -$895K – 740
2024
Q4 		$895K Buy
305,579
+247,342
+425% +$689K ﹤0.01% 639
2024
Q3 		$151K Buy
+58,237
New +$161K ﹤0.01% 700

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

DnB Asset Management's ABCL Position: Q2 2026 in Review

DnB Asset Management opened a new position in AbCellera Biologics (ABCL) in Q2 2026: 677,479 shares worth $5.32M. The stake represents 0.01% of the portfolio and ranks #473 among its holdings. This is a return to the name: DnB Asset Management previously reported a position in ABCL as recently as Q3 2025.

DnB Asset Management first reported a position in ABCL in Q3 2024 and has held it in 4 quarters since. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • DnB Asset Management held 677,479 shares of AbCellera Biologics worth $5.32M as of Q2 2026.
  • AbCellera Biologics was a new DnB Asset Management position in Q2 2026.
  • AbCellera Biologics made up 0.01% of DnB Asset Management's portfolio in Q2 2026, its #473 holding.
  • DnB Asset Management first reported a position in AbCellera Biologics in Q3 2024 and has held it in 4 quarters since.
  • 151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.